Nonspecific Binding Considerations in the Rational Design and Development of Small Molecule COVID-19 Therapeutics.
作者信息
Maurer Tristan S
机构信息
Worldwide Research and Development, Pfizer Inc., Cambridge, Massachusetts, USA.
出版信息
Clin Pharmacol Ther. 2021 Aug;110(2):294-296. doi: 10.1002/cpt.2159. Epub 2021 Feb 5.
Abstract
摘要
相似文献
1
Nonspecific Binding Considerations in the Rational Design and Development of Small Molecule COVID-19 Therapeutics.小分子COVID-19治疗药物合理设计与开发中的非特异性结合考量
Clin Pharmacol Ther. 2021 Aug;110(2):294-296. doi: 10.1002/cpt.2159. Epub 2021 Feb 5.
2
Covalent and non-covalent binding free energy calculations for peptidomimetic inhibitors of SARS-CoV-2 main protease.针对 SARS-CoV-2 主蛋白酶的肽模拟抑制剂的共价和非共价结合自由能计算。
Phys Chem Chem Phys. 2021 Mar 21;23(11):6746-6757. doi: 10.1039/d1cp00266j. Epub 2021 Mar 12.
3
Circadian clock modulating small molecules repurposing as inhibitors of SARS-CoV-2 M for pharmacological interventions in COVID-19 pandemic.昼夜节律钟调节小分子重新用作严重急性呼吸综合征冠状病毒2（SARS-CoV-2）M蛋白的抑制剂，用于2019冠状病毒病大流行的药物干预。
Chronobiol Int. 2021 Jul;38(7):971-985. doi: 10.1080/07420528.2021.1903027. Epub 2021 Apr 6.
4
Optimization Rules for SARS-CoV-2 M Antivirals: Ensemble Docking and Exploration of the Coronavirus Protease Active Site.SARS-CoV-2 M 抗病毒药物的优化规则：冠状病毒蛋白酶活性位点的整体对接和探索。
Viruses. 2020 Aug 26;12(9):942. doi: 10.3390/v12090942.
5
Kidney injury molecule-1 is a potential receptor for SARS-CoV-2.肾损伤分子 1 是 SARS-CoV-2 的潜在受体。
J Mol Cell Biol. 2021 Jul 6;13(3):185-196. doi: 10.1093/jmcb/mjab003.
6
Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.针对高融合活性新兴冠状病毒 SARS-CoV-2 的有效膜融合抑制剂设计。
J Virol. 2020 Jul 1;94(14). doi: 10.1128/JVI.00635-20.
7
The challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeutics.寻找 SARS-CoV-2/COVID-19 治疗方法的艰难途径。
J Antimicrob Chemother. 2020 Sep 1;75(9):2381-2383. doi: 10.1093/jac/dkaa272.
8
Realistic considerations for comparison between SARS-CoV-2 molecular diagnostic assays.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）分子诊断检测方法比较的现实考量
Biomed J. 2021 Jun;44(3):373-374. doi: 10.1016/j.bj.2021.03.006. Epub 2021 Mar 31.
9
The SARS-CoV-2 Cytopathic Effect Is Blocked by Lysosome Alkalizing Small Molecules.溶酶体碱化小分子可阻断新型冠状病毒的细胞病变效应。
ACS Infect Dis. 2021 Jun 11;7(6):1389-1408. doi: 10.1021/acsinfecdis.0c00349. Epub 2020 Dec 21.
10
Toward COVID-19 Therapeutics: A Viewpoint from the Nonprotein Amino Acid Based Synthetic Peptide Design Approach.迈向 COVID-19 疗法：基于非蛋白氨基酸的合成肽设计方法的观点。
ACS Chem Neurosci. 2020 Nov 18;11(22):3701-3703. doi: 10.1021/acschemneuro.0c00661. Epub 2020 Nov 3.
引用本文的文献
1
An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2.一项关于高剂量口服硝唑尼特在健康志愿者中的开放性、适应性、1 期试验：用于 SARS-CoV-2 的抗病毒候选药物。
Clin Pharmacol Ther. 2022 Mar;111(3):585-594. doi: 10.1002/cpt.2463. Epub 2021 Nov 13.
2
Quantitation of tizoxanide in multiple matrices to support cell culture, animal and human research.对多种基质中的替佐硝唑进行定量分析，以支持细胞培养、动物和人体研究。
bioRxiv. 2021 May 28:2021.05.27.445500. doi: 10.1101/2021.05.27.445500.
本文引用的文献
1
Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development.关于在 COVID-19 治疗开发中正确解释血浆和其他生物基质中蛋白结合的共识。
Clin Pharmacol Ther. 2021 Jul;110(1):64-68. doi: 10.1002/cpt.2099. Epub 2020 Nov 21.
2
Existing highly accumulating lysosomotropic drugs with potential for repurposing to target COVID-19.具有潜在重新用于靶向 COVID-19 能力的现有高积累溶酶体靶向药物。
Biomed Pharmacother. 2020 Oct;130:110582. doi: 10.1016/j.biopha.2020.110582. Epub 2020 Jul 30.
3
Does In Vitro Potency Predict Clinically Efficacious Concentrations?体外效力能否预测临床有效浓度？
Clin Pharmacol Ther. 2020 Aug;108(2):298-305. doi: 10.1002/cpt.1846. Epub 2020 May 10.
4
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.洛匹那韦-利托那韦治疗成人重症 COVID-19 患者的临床试验。
N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.
5
Dose Predictions for Drug Design.药物设计中的剂量预测。
J Med Chem. 2020 Jun 25;63(12):6423-6435. doi: 10.1021/acs.jmedchem.9b01365. Epub 2020 Jan 22.
6
Importance of target-mediated drug disposition for small molecules.小分子药物靶标介导处置的重要性。
Drug Discov Today. 2018 Dec;23(12):2023-2030. doi: 10.1016/j.drudis.2018.06.010. Epub 2018 Jun 19.
7
Current Progress Toward a Better Understanding of Drug Disposition Within the Lungs: Summary Proceedings of the First Workshop on Drug Transporters in the Lungs.深入了解肺部药物处置的当前进展：肺部药物转运体第一次研讨会会议纪要
J Pharm Sci. 2017 Sep;106(9):2234-2244. doi: 10.1016/j.xphs.2017.04.011. Epub 2017 Apr 15.
8
Volume of Distribution in Drug Design.药物设计中的分布容积。
J Med Chem. 2015 Aug 13;58(15):5691-8. doi: 10.1021/acs.jmedchem.5b00201. Epub 2015 Apr 1.
9
Do we need to optimize plasma protein and tissue binding in drug discovery?在药物研发中，我们是否需要优化血浆蛋白和组织结合？
Curr Top Med Chem. 2011;11(4):450-66. doi: 10.2174/156802611794480918.
10
The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery.血浆蛋白结合对体内疗效的影响：药物发现中的误解。
Nat Rev Drug Discov. 2010 Dec;9(12):929-39. doi: 10.1038/nrd3287.
Zotero 插件